Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Technical Presentation (April 2022)
4 slides from Invivyd's technical presentation, April 2022
Slide 1: Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody for COVID-19
The 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); P2162 Lisbon, Portugal, April 23-26, 2022 Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19 Christopher M. Rubino,1 Paul G. A
Slide 2: Population PK model provides a robust fit to observed ADG20 concentrations in healthy adults
Population PK model provides a robust fit to observed ADG20 prediction- corrected observed concentrations in healthy adults in a phase 1 study1 Visual predictive check plot Goodness-of-fit plot Circles represent the prediction-corrected observed ADG20 concentrations Long dashed and short dashed blac
Slide 3: Population PK model results are consistent with the intended PK characteristics of ADG20: prolonged half-life
Population PK model results are consistent with the intended PK characteristics of ADG20: prolonged half-life • The median population prediction of elimination half-life was 123 days Parameter, median ADG20 300 mg IM ADG20 500 mg IV ADG20 600 mg IM (range) (n=8) (n=8) (n=8) AUC0-6 months, g*h/L 123
Slide 4: Population PK model results consistent with intended PK: high IM bioavailability and absorption; conclusions
Population PK model results are consistent with the intended PK characteristics of ADG20: high IM bioavailability and absorption CONCLUSIONS • A 2-compartment population pharmacokinetic model with linear elimination and first-order IM absorption provided a precise and unbiased fit to the observed AD
Invivyd — Technical Presentation (April 2022) on 6ix